VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Sanofi vs Synopsys, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Sanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Synopsys, Inc.
SNPS · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Synopsys, Inc.'s moat claims, evidence, and risks.
View SNPS analysisComparison highlights
- Moat score gap: Synopsys, Inc. leads (85 / 100 vs 74 / 100 for Sanofi).
- Segment focus: Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)); Synopsys, Inc. has 2 segments (75.2% in Design Automation).
- Moat breadth: Sanofi has 5 moat types across 3 domains; Synopsys, Inc. has 5 across 2.
Primary market context
Sanofi
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Global
Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)
Research-based drug developer, manufacturer, and marketer
79.8%
Synopsys, Inc.
Design Automation
Electronic design automation (EDA) software and silicon-to-systems simulation & analysis tools
Global
Semiconductor and systems companies (chip/system designers)
Software + hardware tooling provider / platform
75.2%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Sanofi strengths
Synopsys, Inc. strengths
Segment mix
Sanofi segments
Full profile >Pharma (Prescription Medicines)
Oligopoly
Vaccines
Oligopoly
Opella (Consumer Healthcare - Sanofi minority stake)
Competitive
Synopsys, Inc. segments
Full profile >Design Automation
Oligopoly
Design IP
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.